The company trades agricultural commodities, specifically rice, pulses, and grains, sourcing from farmers and aggregators to supply wholesalers and retailers.
The company operates in a highly fragmented commodity trading market with no evidence of pricing power or cost advantages, as reflected by extremely poor historical returns on capital and volatile margins.
Capital has been primarily used for working capital in a low-margin trading business. Recent actions include a failed rights issue and a preferential allotment of warrants to promoters and non-promoters to shore up the balance sheet.
The company's collapse was driven by a fatal combination of governance instability and capital erosion. The resignation of the statutory auditors and constant churn in leadership were early warnings of the internal chaos that eventually led to a total breakdown in financial reporting. As the business continued to funnel capital into related-party advances rather than productive assets, the already negative returns on equity worsened. The failed rights issue signaled a complete loss of market confidence, leaving the firm unable to fund its low-margin trading operations, eventually resulting in a liquidity trap where the remaining assets were consumed by penalties and administrative overhead.
RichFakir rates Onesource Industries & Ventures Ltd's business quality as poor — 26/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Onesource Industries & Ventures Ltd is trading about 34% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Onesource Industries & Ventures Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Onesource Industries & Ventures Ltd's fair value is about ₹2 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →